Potential new treatments in renal cell carcinoma
Emerging roles of nivolumab and cabozantinib for renal cell carcinoma
The risks of combining therapies in renal cell carcinoma and bladder cancer
TKI and checkpoint inhibitor combinations for kidney cancer: the IMmotion151 trial
Combination pembrolizumab and reduced-dose ipilimumab: how low can you go?